Aethlon Medical - 9 Year Stock Price History | AEMD

Historical daily share price chart and data for Aethlon Medical since 2015 adjusted for splits and dividends. The latest closing stock price for Aethlon Medical as of February 23, 2024 is 1.70.
  • The all-time high Aethlon Medical stock closing price was 1707.00 on July 24, 2015.
  • The Aethlon Medical 52-week high stock price is 7.20, which is 323.5% above the current share price.
  • The Aethlon Medical 52-week low stock price is 1.40, which is 17.6% below the current share price.
  • The average Aethlon Medical stock price for the last 52 weeks is 2.85.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Aethlon Medical Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2024 1.8592 2.1650 2.1800 1.6400 1.7000 -22.37%
2023 3.3312 2.8590 6.9990 1.4200 2.1900 -20.48%
2022 10.4600 19.6000 19.9000 2.4800 2.7540 -85.19%
2021 30.9155 25.2000 107.9000 15.4000 18.6000 -24.70%
2020 17.6388 12.5000 43.4000 11.2000 24.7000 156.49%
2019 82.3809 237.0000 237.0000 8.3580 9.6300 -96.13%
2018 193.0364 174.0000 285.0000 140.0250 249.0000 46.90%
2017 329.9178 602.7000 712.5000 120.1500 169.5000 -73.10%
2016 806.6219 945.0000 1154.9999 616.5000 630.0000 -38.14%
Sector Industry Market Cap Revenue
Medical Medical - Health Maintenance Organizations $0.004B $0.001B
Aethlon Medical, Inc. is a development stage medical device company focused on expanding the applications of our Hemopurifier (R) platform technology, which is designed to rapidly reduce the presence of infectious viruses and other toxins from human blood. In this regard, its core focus is the development of therapeutic devices that treat acute viral conditions, chronic viral diseases and pathogens targeted as potential biological warfare agents. The Hemopurifier(R) combines the established scientific principles of affinity chromatography and hemodialysis as a means to mimic the immune system's response of clearing viruses and toxins from the blood before cell and organ infection can occur. The Hemopurifier(R) cannot cure viral conditions but can prevent virus and toxins from infecting unaffected tissues and cells. The company has completed pre-clinical blood testing of the Hemopurifier(R) to treat HIV and Hepatitis-C, and have completed human safety trials on Hepatitis-C infected patients in India.
Stock Name Country Market Cap PE Ratio
UnitedHealth Group (UNH) United States $487.658B 20.99
Cigna Group (CI) United States $100.731B 13.72
Humana (HUM) United States $43.786B 13.96
Centene (CNC) United States $42.907B 12.05
Molina Healthcare (MOH) United States $23.755B 19.47
Select Medical Holdings (SEM) United States $3.658B 14.32
Joint (JYNT) United States $0.145B 75.61